Corcept Therapeutics (CORT) Net Income towards Common Stockholders (2010 - 2026)

Corcept Therapeutics has disclosed Net Income towards Common Stockholders across 17 years of filings, most recently posting -$31.2 million for Q1 2026.

• Net Income towards Common Stockholders for Q1 2026 came in at -$31.2 million, down 253.8% year-over-year; the trailing twelve-month figure through Mar 2026 was $46.7 million (down 64.77% YoY), and the FY2025 annual result was $98.2 million, down 29.74% from the prior year.
• Net Income towards Common Stockholders came in at -$31.2 million for Q1 2026 at Corcept Therapeutics, down from $23.9 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $46.7 million in Q3 2024 to a low of -$31.2 million in Q1 2026.
• The 5-year median for Net Income towards Common Stockholders is $27.4 million (2022), against an average of $24.3 million.
• Across the five-year window, Net Income towards Common Stockholders jumped 88.37% in 2023 and plunged 253.8% in 2026, its largest moves.
• Corcept Therapeutics' Net Income towards Common Stockholders stood at $16.5 million in 2022, then surged by 88.37% to $31.1 million in 2023, then declined by 2.42% to $30.4 million in 2024, then decreased by 21.34% to $23.9 million in 2025, then plunged by 230.53% to -$31.2 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$31.2 million (Q1 2026), $23.9 million (Q4 2025), and $19.4 million (Q3 2025), per Business Quant data.